



U.S. Fish & Wildlife Service

The Aquatic Animal Drug Approval Partnership Program

Fact Sheet: Oxytetracycline Bath Marking INAD 9033

[For detailed information see INAD Study Protocol]

INAD objective/purpose:	Collect supportive and pivotal data needed to establish the effectiveness of oxytetracycline (OTC) to mark otoliths in a variety of fish species.
Drug name:	Terramycin-343
Source of drug:	Pfizer, Inc.
Address:	1107 South 291 Highway Lee's Summit, MO 64081
Contact:	Phone: 816-524-5580; Fax: 816-525-7360
Target pathogen(s):	Not Applicable
Method of administration:	Immersion: standing-bath treatment only
Treatment dosage:	500 milligrams OTC per liter
Treatment regimen:	6-hour treatment (all species) Single treatment only
Withdrawal period:	None. Fish may be released immediately following treatment.
Required test parameters:	Investigator must collect mark retention and mortality data. Investigator should also report general fish behavior and any adverse effects relating to treatment.
Limitations or restrictions on use of drug:	Treatment is restricted to fish having a body weight of 2 grams or less. Investigator must follow all instructions in the Study Protocol for INAD 9033 regarding drug acquisition and handling, fish treatment and disposition, and data reporting requirements. Drug discharge must be in compliance with local NPDES permitting requirements.
Required INAD fee:	none
AADAP Contact Information:	Ms. Bonnie Johnson, FWS-AADAP Phone: 406-587-9265 ext 136 Fax: 406-582-0242 email: bonnie_johnson@fws.gov